Please enable Javascript
Advanced Urothelial Carcinoma
Advertisement
IMvigor130: Updated OS Data From the Final Analysis
Zachary Bessette
ASCO 2023
|
June 2, 2023
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
Read More
KEYNOTE-361: Complete Response Outcomes With First-line Pembrolizumab or Platinum-Based Chemotherapy
Emily Menendez
ASCO 2023
|
June 1, 2023
A post-hoc exploratory analysis of the KEYNOTE-361 study was presented at the 2023 ASCO annual meeting.
Read More
Drs. Koshkin, Basu on Clinical Practice Patterns for Adjuvant Therapy of ctDNA-Positive MIBC
Arnab Basu, MD, MPH, FACP
Advanced Urothelial Carcinoma
|
June 1, 2023
Drs. Koshkin and Basu comment on the best available treatment approach for patients with ctDNA-positive MIBC after surgery.
View More
Drs. Koshkin, Basu on ctDNA and MRD Considerations for Adjuvant Therapy After Radical Cystectomy
Arnab Basu, MD, MPH, FACP
Advanced Urothelial Carcinoma
|
June 1, 2023
Drs. Koshkin, Basu break down treatment considerations based on ctDNA status after radical cystectomy, among other factors.
View More
Drs. Koshkin, Basu on MRD, ctDNA, and Liquid Biomarker Use in Bladder Cancer
Arnab Basu, MD, MPH, FACP
Advanced Urothelial Carcinoma
|
June 1, 2023
Drs. Koshkin and Basu discuss how ctDNA are being evaluated for disease recurrence, response monitoring in advanced UC.
View More
EV-103 Cohort A: Long-term Outcomes of EV Plus Pembrolizumab in First-line mUC
Zachary Bessette
ASCO 2023
|
May 30, 2023
EV plus pembrolizumab continues to demonstrate promising survival trends with durable responses in first-line la/mUC.
Read More
Emerging Targeted Therapies in Bladder Cancer: Frontline Options and Beyond
Arlene O. Siefker-Radtke, MD
Advanced Urothelial Carcinoma
|
May 26, 2023
Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.
Read More
Long-term Safety of Avelumab First-line Maintenance for Advanced UC
Zachary Bessette
ASCO 2023
|
May 26, 2023
Post hoc analyses from JAVELN Bladder 100 shed light on the long-term safety profile of avelumab first-line maintenance.
Read More
Drs. Shoag, Zhu on Whether ICI Combinations Lead to Durable Survival Benefit in Metastatic UC
Jonathan E. Shoag, MD
Advanced Urothelial Carcinoma
|
May 25, 2023
Drs. Shoag and Zhu describe their recent analysis on the data supporting ICI use in patients with cisplatin-ineligible mUC.
View More
Maintenance Avelumab Use Increased Postapproval, Has Moderate Uptake
Emily Menendez
Advanced Urothelial Carcinoma
|
May 12, 2023
After maintenance approval, an estimated 42.8% of patients received first-line ICI with either pembrolizumab or atezolizumab.
Read More
Dr. Jonathan Rosenberg on Whether EV Should Be a New Standard of Care for mUC
Jonathan Rosenberg, MD
Advanced Urothelial Carcinoma
|
May 9, 2023
Dr. Rosenberg discusses EV plus pembrolizumab, how the combination is being investigated in clinical trials, and toxicity.
View More
Do ICIs Offer Long-term Survival for Patients With mUC?
Emily Menendez
Advanced Urothelial Carcinoma
|
May 5, 2023
Clinical trials that evaluated pembrolizumab, avelumab, and nivolumab for urothelial carcinoma were analyzed.
Read More
Association Between Immune-Related Adverse Events, Outcomes After ICIs for mUC
Zachary Bessette
AUA 2023: Focus on Bladder Cancer
|
April 28, 2023
IMvigor210 and IMvigor211 shed light on the association between irAEs and outcomes after receiving atezolizumab for aUC.
Read More
First-line Avelumab Maintenance for Advanced UC: Long-term Results of JAVELIN Bladder 100
Zachary Bessette
AUA 2023: Focus on Bladder Cancer
|
April 28, 2023
Long-term exploratory analyses of subgroups defined by response to first-line chemotherapy in the JAVELIN Bladder 100 trial.
Read More
Dr. Plimack on Whether Hypomethylating Agents Induce Immune Activation in aUC Resistant to ICI
Elizabeth Plimack, MD, MS
Advanced Urothelial Carcinoma
|
April 21, 2023
Dr. Plimack discusses the results of her phase 2 study on hypomethylating agents, and gives a preview of research to come.
View More
Dr. Elizabeth Plimack on a Hypomethylating Agent Plus Anti-PD-L1 for mUC After Disease Progression
Elizabeth Plimack, MD, MS
Advanced Urothelial Carcinoma
|
April 21, 2023
Elizabeth Plimack, MD, MS, provides an overview of a recent phase 2 trial of guadecitabine plus atezolizumab for mUC.
View More
Genetic Variables of Urothelial Carcinoma Demonstrate Sensitivity to Immune Checkpoint Inhibitors
Emily Menendez
Advanced Urothelial Carcinoma
|
April 14, 2023
A study carried out whole-exome sequencing on tumor specimens taken from 88 patients with advanced UC treated with ICIs.
Read More
Dr. Rana McKay on the Enfortumab Vedotin Combo Receiving an FDA Nod for Advanced Urothelial Cancer
Rana McKay, MD
Advanced Urothelial Carcinoma
|
April 10, 2023
Dr Rana McKay shares how the approval of enfortumab vedotin plus pembrolizumab impacts patients with advanced UC.
View More
FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv With Pembrolizumab for Advanced UC
Zachary Bessette
Advanced Urothelial Carcinoma
|
April 4, 2023
Enfortumab vedotin-ejfv with pembrolizumab is now approved for patients with locally advanced or metastatic UC.
Read More
Nivolumab With or Without Ipilimumab for Metastatic Urothelial Carcinoma
Emily Menendez
Advanced Urothelial Carcinoma
|
March 17, 2023
The TITAN-TCC trial examined the safety and efficacy of nivolumab induction with ipilimumab as an immunotherapeutic boost.
Read More
Load More
Advertisement
Advertisement
Advertisement